http://dx.doi.org/10.1016/j.phymed.2010.09.001">
 

Document Type

Journal Article

Authors

Desmond Kwok-Po Hau, Research and Development Division, School of Chinese Medicine, Hong Kong Baptist University
Guo-Yuan Zhu, Research and Development Division, School of Chinese Medicine, Hong Kong Baptist University
Alexander Kai-Man Leung, Research and Development Division, School of Chinese Medicine, Hong Kong Baptist University
Raymond Siu-Ming Wong, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong
Gregory Yin-Ming Cheng, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong
Paul Bo-San Lai, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong
Sze-Wai Tong, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong
Fung-Yi Lau, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong
Kit-Wah Chan, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong
Wai-Yeung Wong, Department of Chemistry, Hong Kong Baptist UniversityFollow
Kim-Hung Lam, Institute of Textiles and Clothing and Applied Biology, The Hong Kong Polytechnic University
Chor-Hing Cheng, Institute of Textiles and Clothing and Applied Biology, The Hong Kong Polytechnic University
Filly Cheung, Institute of Textiles and Clothing and Applied Biology, The Hong Kong Polytechnic University
Chung-Hin Chui, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong
Roberto Gambari, BioPharmaNet, Department of Biochemistry and Molecular Biology, The University of Ferrara
David Wang-Fun Fong, Institute of Textiles and Clothing and Applied Biology, The Hong Kong Polytechnic University

Department/Unit

Department of Chemistry

Title

In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma

Language

English

Abstract

We have investigated the potential in vivo anti-tumour activity of corilagin using the Hep3B hepatocellular carcinoma cell line and an athymic nude mice xenograft model. The purity of corilagin was confirmed by high performance liquid chromatographic analysis. Corilagin was administrated intraperitoneally for a continuous period of 7 days at a concentration of 15. mg/kg of body weight per day. A significant inhibition of tumour growth was observed when treated mice are compared with control groups. Furthermore, analysis of enzymes markers of liver function, including alanine aminotransferase and asparate aminotransferase, suggested that current therapeutic dosage of corilagin did not exert adverse effect on liver. Our observations support the view that corilagin is considerably effective to retard the in vivo growth of xenografted Hep3B hepatocellular carcinoma. © 2010 Elsevier GmbH.

Keywords

Corilagin, Hepatocellular carcinoma, Xenograft model

Publication Date

2010

Source Publication Title

Phytomedicine

Volume

18

Issue

1

Start Page

11

End Page

15

Publisher

Elsevier

ISSN (print)

09447113

ISSN (electronic)

1618095X

This document is currently not available here.

Share

COinS